This Week in Pediatrics — Jun 24, 2026

Welcome to This Week in Pediatrics. This week we are covering ten notable papers spanning critical advances in neonatal development and monitoring, novel interventions for complex congenital and genetic conditions, and the long-term trajectories of pediatric diseases into adolescence and young adulthood. Let us dive in.

We begin in the neonatal intensive care unit, where balancing immediate therapeutic needs with long-term neurodevelopmental outcomes remains one of our greatest clinical challenges. Postnatal fentanyl is commonly administered for sedation in preterm infants, but its systemic effects are increasingly under scrutiny. A cohort study published in Pediatric Research by David and colleagues investigated how postnatal fentanyl exposure associates with the gut microbiome and subsequent neurodevelopment up to age eight [1]. The researchers found that fentanyl exposure during neonatal intensive care unit hospitalization is associated with decreased fecal microbiome richness, a negative association with beneficial microbial taxa such as Actinobacteriota and Bacteroidia, and increased rates of constipation. Furthermore, it was linked to an increase in microbiome-derived metabolites involved in inflammation and altered microbial virulence. Crucially, increased duration of postnatal fentanyl exposure was associated with worse cognitive scores on the Bayley scales at two years of age and lower intelligence quotient composite scores on the Wechsler scale at three to eight years of age. Interestingly, virulence factors present in the microbiome mediated the association between fentanyl and cognitive outcomes at two years old. Clinically, these findings suggest that early gut microbiota differences associated with fentanyl may have lasting impacts on cognitive development, urging clinicians to minimize cumulative opioid exposure whenever possible.

Moving from pharmacological exposures to therapeutic interventions for neonatal encephalopathy, the clinical management of late-preterm infants continues to spark debate. A commentary in Pediatric Research by El-Dib and colleagues tackles the ongoing controversy surrounding therapeutic hypothermia in infants born at thirty-five weeks' gestation [2]. While randomized clinical trials and real-world observational studies often show discordant findings in this borderline population, clinical guidance is evolving. The authors highlight that because of this uncertainty, clinical practice varies widely across institutions. Current American Academy of Pediatrics guidance explicitly recommends parental discussion and shared decision-making in these preference-sensitive clinical scenarios. The authors argue that shared decision-making is essential but inconsistently implemented, and they emphasize the importance of transparent communication, parental engagement, and structured clinician training. They also advocate for pragmatic, parent-informed research approaches to generate timely and clinically meaningful evidence in this complex population. For practicing neonatologists, this is a reminder that when clear-cut evidence is lacking, the path forward must be paved with collaborative, transparent communication with families.

In addition to neuroprotection, metabolic stability is a cornerstone of neonatal care, particularly the avoidance of hypoglycemia. In another study from Pediatric Research, Kusaka and colleagues evaluated a novel, non-invasive method for continuous blood glucose estimation in term neonates [3]. Traditional continuous glucose monitors are invasive and expensive, but this new approach estimates blood glucose using the phase delay between oxy- and deoxyhemoglobin waveforms, captured via standard pulse oximetry probes and expressed as a metabolic index. In a study of thirty term neonates on their second postnatal day, the researchers found that the corrected metabolic index showed a significant positive correlation with plasma glucose levels. Interestingly, both the slope and intercept of this relationship differed from adult values, indicating that neonatal glucose estimation requires age-specific calibration. If validated in larger, more diverse cohorts, this low-cost, non-invasive technique could revolutionize bedside hypoglycemia surveillance, sparing infants from repeated, painful heel sticks.

Next, we turn to the rapidly advancing frontiers of fetal surgery and precision medicine, where novel technologies are transforming the management of congenital and genetic disorders. In The Lancet, Russo and colleagues published a phase-one trial of a novel tracheal occlusion device, known as the Smart-TO balloon, for fetuses with congenital diaphragmatic hernia [6]. Historically, a major drawback of fetoscopic endoluminal tracheal occlusion has been the need for a second invasive intrauterine procedure to remove the balloon and establish airway patency before birth. This new device is designed to spontaneously deflate when exposed to a strong magnetic field, such as that of a magnetic resonance imaging machine. In a study of forty-six fetuses who had the device successfully placed, the magnetic resonance-induced deflation rate was one hundred percent, and at birth, the empty balloon was completely outside the airways in all infants. While there were two cases of tracheomalacia that resolved by discharge, and fourteen neonatal deaths due to severe pulmonary hypoplasia, no serious adverse events were related to the device itself. This represents a substantial advance in fetal surgery, offering a safer, non-invasive way to restore the airway before delivery.

While fetal surgery addresses structural anomalies, precision pharmacotherapy is beginning to target the intracellular pathways driving genetic pediatric cardiomyopathies. In Pediatric Research, Ruiz-Velasco and colleagues investigated mavacamten, a cardiac myosin inhibitor approved for obstructive hypertrophic cardiomyopathy, in a pre-clinical model of RASopathy-associated hypertrophic cardiomyopathy [7]. Activating mutations in the RAS-mitogen-activated protein kinase pathway account for about twenty percent of pediatric hypertrophic cardiomyopathy cases and are associated with poor clinical outcomes. Using human induced pluripotent stem cell-derived cardiomyocytes with a BRAF mutation, the investigators demonstrated that these cells exhibit characteristic hypertrophy and hypercontractility. Despite having enhanced mitochondrial respiratory capacity, the mutant cells suffered from severe energy depletion and adenosine triphosphate deficiency under rapid pacing. Crucially, treatment with mavacamten normalized mitochondrial respiration and excessive energy consumption, proving that hypercontractility itself is the primary driver of metabolic stress in these cells. This pre-clinical success suggests that mavacamten holds significant potential as a therapeutic option to restore energetic balance in pediatric patients with RASopathy-associated cardiomyopathy.

In another area of genetic disease, the widespread use of highly effective modulator therapies has transformed cystic fibrosis care, but has also raised new questions about long-term metabolic side effects. A study in Pediatric Research by Ünlü and colleagues evaluated the effect of cystic fibrosis transmembrane conductance regulator, or CFTR, modulator therapies on lipid profiles in children [8]. While adult studies have raised concerns about dyslipidemia, pediatric data have been sparse. In this retrospective study of twenty-six children with a median age of eleven years, most of whom were receiving elexacaftor, tezacaftor, and ivacaftor, the researchers compared metabolic markers at baseline and six months after starting therapy. They observed significant improvements in body mass index and lung function. However, although there were minor numerical increases in cholesterol and triglycerides, none of these lipid changes reached statistical significance, and there was no association between weight gain and lipid alterations. This provides reassuring real-world evidence that, at least in the short term, pediatric patients experience the profound pulmonary and nutritional benefits of CFTR modulators without experiencing clinically meaningful lipid deterioration.

We now shift our focus to preventive health and the systems-level challenges of vaccine delivery, examining how we can better protect infants and children from vaccine-preventable respiratory illnesses. In a large observational cohort study published in Pediatrics, Archer and colleagues evaluated the relationship between maternal vaccination during pregnancy and subsequent infant vaccine uptake [5]. Analyzing over eighty-two thousand mother-infant pairs, the researchers found that maternal vaccination was a massive predictor of infant coverage. Infants whose mothers received a COVID-19 vaccine during pregnancy were nearly ten times more likely to receive their own COVID-19 vaccine in the first year of life compared to those whose mothers were unvaccinated. Similarly, maternal influenza vaccination during pregnancy was associated with a nearly four-fold increase in infant influenza vaccination. This strong concordance highlights a vital clinical opportunity: by focusing efforts on improving maternal vaccine coverage and counseling during pregnancy, pediatricians and obstetricians can simultaneously build a foundation for improved vaccine uptake in the infant's first year of life.

While outpatient maternal counseling is key, the inpatient setting represents another underutilized touchpoint for catching up on missed pediatric vaccinations. Also in Pediatrics, Bryan and colleagues conducted a qualitative study across eleven United States children's hospitals to explore the barriers and facilitators of inpatient vaccine delivery [4]. Despite a significant number of hospitalized children being behind on their immunizations, inpatient administration remains rare. Through interviews with hospitalists, nurses, and pharmacists, several key themes emerged. First, vaccine administration is often delayed until the hectic discharge window, which frequently leads to the opportunity being missed entirely. Second, participants noted that vaccinating during a hospital stay is a vital safety net for families with poor access to primary care. Finally, the study revealed that inpatient vaccine workflows are rarely standardized and suffer from a lack of clinical ownership. Addressing these operational barriers through multidisciplinary, standardized workflows is essential if we are to leverage hospitalizations as a tool to close immunization gaps.

Finally, we examine the long-term health trajectories of pediatric and adolescent populations, looking at how early-life illnesses and biological aging shape chronic disease risk. In Pediatrics, Chiang and colleagues published a prospective cohort study from Lima, Peru, investigating post-tuberculosis lung disease in adolescents [10]. While tuberculosis is curable, the long-term respiratory sequelae in young survivors are poorly understood. The researchers compared one hundred and one adolescent tuberculosis survivors with matched healthy controls over a twenty-four-month period. Using spirometry, oscillometry, and quality-of-life questionnaires, they found that even after successful bacteriological cure, tuberculosis survivors suffered from persistent, symptomatic chronic lung disease. They had significantly worse lung function, including reduced forced expiratory volume and increased airway resistance, alongside structural damage on chest computed tomography, such as bronchiectasis and architectural distortion. This study underscores that adolescent tuberculosis survivors require structured, long-term respiratory assessments and rehabilitation well beyond the completion of their antimicrobial therapy.

The concept of early-life exposures leaving a permanent biological footprint is further illustrated by a study on biological aging and early-onset cancer risk. Published in Nature Medicine, Tian and colleagues analyzed data from over one hundred and fifty-four thousand young adults to understand the rising global incidence of early-onset cancers [9]. They measured systemic biological aging using PhenoAge and found that biological age has been steadily increasing across successive birth cohorts, independent of genetic risk. This advanced biological aging relative to chronological age was significantly associated with a slightly higher risk of early-onset solid tumors, particularly gastrointestinal, lung, and uterine cancers. Furthermore, organ-specific analyses linked immune system aging to lung cancer and adipose tissue aging to colorectal cancer. These findings, validated in the United States All of Us Research Program, suggest that accelerated biological aging serves as a key driver of early-onset cancers, pointing to a critical need for early-life preventive strategies and lifestyle interventions to slow the biological clock before chronic disease manifests.

If you only have time for one paper this week, make it the clinical trial in The Lancet evaluating the Smart-TO balloon for fetal congenital diaphragmatic hernia [6]. This study represents a major technological leap forward in fetal surgery, demonstrating that we can successfully achieve tracheal occlusion and completely non-invasive, magnetic resonance-induced balloon deflation, eliminating the need for a second high-risk intrauterine procedure and simplifying the care of these critically ill neonates.

Here are the key takeaways from this week in Pediatrics. First, postnatal fentanyl exposure in the neonatal intensive care unit is associated with significant alterations in the infant gut microbiome and worse cognitive outcomes up to age eight, reminding us to minimize cumulative opioid exposure whenever possible [1]. Second, for late-preterm infants born at thirty-five weeks' gestation with neonatal encephalopathy, the clinical evidence for therapeutic hypothermia remains mixed, making shared decision-making and transparent communication with parents essential [2]. Third, maternal vaccination during pregnancy is a powerful predictor of infant immunization, with infants of vaccinated mothers being up to ten times more likely to receive their own COVID-19 and influenza vaccines [5]. Fourth, pediatric tuberculosis survivors suffer from persistent, symptomatic chronic lung disease and structural airway damage long after achieving bacteriological cure, highlighting the need for ongoing respiratory follow-up [10]. And fifth, cystic fibrosis modulator therapies improve pulmonary and nutritional outcomes in children without causing clinically meaningful deterioration in lipid profiles over six months of treatment [8].

That's your roundup for This Week in Pediatrics. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.